A 68-year-old woman with dilated cardiomyopathy (EF 25%) and chronic atrial fibrillation presents with palpitations and dyspnea. Her current medications include ACE inhibitor, beta-blocker, and diuretics. She requires both rate control and rhythm control. Which antiarrhythmic is the drug of choice for rhythm control in this patient?

Explanation

## Rhythm Control in Atrial Fibrillation with Reduced Ejection Fraction **Key Point:** In patients with atrial fibrillation and reduced ejection fraction (EF <40%), amiodarone is the only antiarrhythmic drug that is both effective for rhythm control AND safe in the setting of systolic dysfunction. All other Class I and Class III antiarrhythmics are contraindicated or have limited efficacy due to their negative inotropic effects. ### Why Amiodarone is Mandated in Reduced EF 1. **Unique safety profile:** Despite being a Class III agent (potassium channel blocker), amiodarone has mild negative inotropic effects and does NOT worsen ejection fraction or precipitate cardiogenic shock. 2. **Efficacy:** Most effective antiarrhythmic for AF rhythm control; conversion rates 50–70% at 6 months. 3. **No proarrhythmia risk:** Unlike Class I agents, amiodarone does not increase mortality in patients with structural heart disease (CAST trial exemption). 4. **Mechanism:** Blocks all four ion channels (I, II, III, IV), providing broad-spectrum antiarrhythmic action with additional beta-blocking and calcium channel-blocking properties. ### Contraindications of Other Agents in Reduced EF | Agent | Class | Mechanism | EF <40% Safety | Reason for Contraindication | |-------|-------|-----------|----------------|-----------------------------| | **Amiodarone** | III | K^+^ channel blocker | ✓ **SAFE** | **Minimal negative inotropy; no increase in mortality** | | Flecainide | IC | Na^+^ channel blocker | ✗ Contraindicated | Strong negative inotrope; increases mortality in HF (CAST trial) | | Propafenone | IC | Na^+^ channel blocker | ✗ Contraindicated | Strong negative inotrope; proarrhythmic in structural disease | | Sotalol | III + II | K^+^ blocker + beta-blocker | ⚠ Relative CI | Negative inotrope; risk of torsades; not recommended in EF <40% | | Dofetilide | III | K^+^ channel blocker | ⚠ Relative CI | Requires renal dosing; risk of torsades; not preferred | **High-Yield:** The CAST trial (1989) demonstrated that Class IC antiarrhythmics (flecainide, encainide) INCREASED mortality in post-MI patients with reduced EF, establishing the principle that negative inotropic drugs are harmful in systolic dysfunction. Amiodarone is the exception because it does not increase mortality. **Mnemonic:** **"SAFE in Systolic dysfunction = Amiodarone For Ejection fraction <40%"** — Amiodarone is the only antiarrhythmic safe for rhythm control in HF. **Clinical Pearl:** Amiodarone loading: 600 mg daily for 1 week, then 400 mg daily for 3 weeks, then 200 mg daily maintenance. IV amiodarone (150 mg bolus over 10 min, then 1 mg/min infusion) is used for acute AF in hospitalized patients with HF. **Warning:** Amiodarone has significant side effects (thyroid dysfunction, pulmonary fibrosis, hepatotoxicity, QT prolongation) and requires baseline and periodic monitoring (TSH, LFTs, chest X-ray, ECG). However, these toxicities are acceptable trade-offs in patients with reduced EF who have no other safe alternatives.